Introduction
Angiotensin II (Ang II)-mediated activation of the angiotensin type 1 A receptor (AT1 A R), a member of the seven-transmembrane receptor (7TMR) family, leads to the initiation of both G q protein-dependent and -independent signaling cascades. G q protein-dependent signaling involves 2 nd messenger generation (e.g. diacylglycerol (DAG) accumulation), ultimately leading to a hypertrophic response that can be maladaptive over time, but that can be attenuated via the use of angiotensin receptor blockers (ARBs) [1; 2] . G protein-independent signaling involves recruitment of β-arrestins 1 and/or 2 (βarr1/2) [3] , multifunctional scaffold proteins that are involved in numerous cell signaling events including initiation of receptor internalization, activation of protein kinase and anti-apoptotic cascades and transactivation of epidermal growth factor receptor [3; 4; 5] . β-arrestin-dependent signaling has been shown to be both physiologically relevant and beneficial in the cardiovascular system. In cardiomyocytes, β-arrestin signaling mediates protection against chronic sympathetic stimulation [6] and increases contractility in response to AT1 A R stimulation [7] . Additionally, β-arrestin signaling has been shown to activate anti-apoptotic pathways downstream of AT1 A R in vascular smooth muscle cells [5] . Thus, an agent that acts selectively at the AT1 A R to induce beneficial β-arrestin signaling without increasing detrimental G q protein activity could effective in the treatment of cardiovascular disorders.
Recent studies have shown that synthetic agonists for the transcription factor peroxisome proliferator-activated receptor γ (PPARγ) oppose Ang II-mediated effects, reducing the hypertrophic response of cardiomyocytes to administration of Ang II as well as decreasing Ang II-mediated signaling in blood vessels and subsequent development of hypertension [8; 9; 10; 11] . Synthetic agonists for PPARγ are typically used in the treatment of Type II diabetes to increase insulin sensitivity [12] . These agents have been shown experimentally and clinically to improve cardiovascular function via increased vascular reactivity and cardiac function, decreased inflammation and reduced visceral fat storage (as reviewed in [13] min with ice-cold 0.2% Triton-X 100 in PBS. Cells were blocked for 1hr and all antibodies were diluted in 0.1% BSA in PBS. HA-AT1 A R was visualized using monoclonal anti-HA clone HA-7
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(Thermo Scientific, Rockford IL) at 1:1000 for 1hr. Samples were imaged using a Leica DMI6000B inverted microscope with the Leica DFC360 FX 1.4-megapixel monochrome digital camera. This system was controlled by and deconvolution carried out using Leica AF6000
software. Each condition was performed independently 3 times.
Chemical crosslinking and immunoprecipitation. Crosslinking was performed as previously described [19] . Immunoprecipitation (IP) of samples was performed using 200 to 500 µg protein and overnight incubation at 4°C with 25 µL of monoclonal anti-HA agarose or anti-FLAG M2
agarose (Sigma-Alrich). βarr1/2 recruitment was normalized to total βarr1/2 levels and amount of immunoprecipitated HA-AT1 A R or FLAG-β1AR.
Immunoblotting. Following drug treatment, cells were rinsed in ice-cold PBS then collected
and lysed in buffer containing 1% NP40, 20mM Tris, pH 7.4, 137mM NaCl, 100µg/mL PMSF, 10% Glycerol, 10mM NaF, 0.36mg/mL Na 3 VO 4 and EDTA-free HALT protease inhibitor cocktail (Thermo Scientific, Rockford, IL). Protein estimation was carried using Pierce 660nm
Protein Assay Reagent (Thermo Scientific), and immunoblotting of samples performed as previously described [19] . The LI-COR biosciences Odyssey system was used for detection of immunoblots using anti-β-arrestin1/2 (D24H9) at 1:5,000 (Cell Signaling Technology, Danvers, MA) and anti-FLAG M2 at 1:10,000 (Sigma-Aldrich). IRDye800 conjugated anti-HA epitope tag was used at 1:20,000 (Rockland, Gilbertsville, PA). Non-conjugated primary antibodies were detected with IRDye680 Donkey anti-rabbit IgG (H+L) at 1:5,000 in Odyssey Blocking
Buffer (LI-COR Biosciences, Lincoln, NE).
DAGR assay. HA-AT1 A R cells transfected with DAGR were seeded into 35mm glass-bottom confocal dishes (MatTek Corporation, MA) coated with 10 µg/mL fibronectin. Prior to assay, cells were rinsed and incubated in buffer containing 125mM NaCl, 5mM KCl, 1.5mM MgCl 2 ,
1.5mM CaCl 2 , 10mM glucose, 0.2% BSA, 10mM HEPES, pH 7.4. Cells were stimulated with drugs and underwent fluorescence resonance energy transfer (FRET) analysis as described previously [20] , with quantification of the DAGR ratio over time calculated as FRET intensity/mCFP intensity, normalized to baseline.
Cardiomyocyte Contractility
Mice used in these studies were C57BL/6 mice and βarr2 knockout mice (described previously, [7; 21] ), 3-6 months old and 25-40g. 10-15 cardiomyocytes were used per treatment per heart.
Animals were handled according to approved protocols and animal welfare regulations of the Institutional Review Board at Duke University Medical Center. Myocyte isolation, visualization and analysis were carried out as previously described [22; 23] .
Statistical Analysis
Data are presented as mean±s.e.m. All statistical analyses were performed using One-way ANOVA with Tukey's multiple comparisons test via Prism 5.0 software.
Results
Troglitazone induces AT1 A R internalization and β-arrestin recruitment without activation of G q protein. (Fig. 1) and previously shown by others to mediate PPARγ-independent effects [14; 25] . These data show that while Trog has no effect on AT1 A R-coupled G q protein activity, it does induce βarr1/2 recruitment to the AT1 A R and promote receptor internalization.
Troglitazone-mediated β-arrestin recruitment is selective for the AT1 A R
Trog-mediated βarr1/2 recruitment to the AT1 A R suggests that Trog acts at the AT1 A R itself to stimulate the response, thus we tested whether β-arrestin recruitment could be blocked with an ARB. Using matched submaximal concentrations of Trog (50µM) and Ang II (5nM) for βarr1/2 recruitment, the ability of the ARB, losartan (Los), to block Trog-mediated βarr1/2 recruitment to AT1 A R was assessed via immunoprecipitation. As a positive control for Losmediated inhibition of the AT1 A R, Ang II-mediated βarr1/2 recruitment to HA-AT1 A R was prevented by Los pretreatment (Fig. 3A) . Similarly, Trog-mediated βarr1/2 recruitment to HA-AT1 A R was ablated by pretreatment with Los. These results indicate that Trog acts directly at the AT1 A R to induce βarr1/2 recruitment, an effect that can be surmounted with an ARB.
To investigate whether βarr1/2 recruitment in response to Trog is selective to the AT1 A R or is a nonselective response to high concentrations of Trog at 7TMRs in general, we tested the ability of Trog to induce recruitment of βarr1/2 to the β1-adrenergic receptor (β1AR). FLAG-β1AR cells were stimulated with the highest concentration of Trog (100µM) shown to induce βarr1/2 recruitment to the AT1 A R, or isoproterenol (ISO, 1µM) as a positive control for βarr1/2 9 recruitment to the β1AR. While ISO stimulation induced a significant increase in βarr1/2 recruitment to the β1AR, Trog was unable to promote β-arrestin recruitment to the β1AR (Fig.   3B ), indicating that Trog-induced βarr1/2 recruitment is selective for the AT1 A R.
Troglitazone increases cardiomyocyte contractility via the AT1 A R in a β-arrestin-
dependent manner
To determine if a PPARγ agonist induces a physiologic effect mediated by AT1 A R signaling, we measured the effect of Trog on the contractility of freshly isolated murine cardiomyocytes. Treatment of wild-type cardiomyocytes with concentrations of Trog that were shown to induce βarr1/2 recruitment to AT1 A R (50-100µM, Fig. 2B ) resulted in a significant increase in both the percentage and rate of cell shortening (Fig. 4A, black bars) . These Trogmediated effects on contractility were statistically indistinguishable from those of Ang II.
Importantly, the Trog-mediated increase in cardiomyocyte contractility was blocked by pretreatment with an ARB (valsartan, Val). These results confirm our observation that Trog acts via the AT1 A R and indicate that this interaction is capable of mediating a physiologic increase in cardiomyocyte contractility.
Since βarr2 plays a role in AT1 A R-mediated myocyte contractility [7] , we tested whether βarr2 signaling is required for Trog-mediated effects on myocyte contractility. Cardiomyocytes isolated from βarr2 knockout mice (βarr2-KO) exhibited blunted cell shortening responses to both Ang II and Trog stimulation that were not statistically different from untreated cells (Fig.   4A , grey bars). To ensure that βarr2-KO cardiomyocytes were responsive to a contractile stimulus, they were treated with ISO, which produced a significant increase in contractile response. Comparison of the contractility increases achieved in wild-type versus βarr2-KO cardiomyocytes revealed a significantly diminished response to both Ang II and Trog in the absence of β-arr2 (Fig. 4B) . Thus, βarr2 is a key mediator of Trog-induced cardiomyocyte contractility.
Discussion
In this study, we show that the PPARγ agonist Trog acts at the AT1 A R to induce AT1 A R internalization and ARB-sensitive recruitment of βarr1/2, in the absence of G q protein activation.
Moreover, we show that Trog increases cardiomyocyte contractility in an ARB-sensitive manner and is, at least partially, β-arrestin2-dependent. Although PPARγ agonists classically activate
PPARγ to mediate gene transcription, it has also been shown that these agents can exert PPARγ-independent cell signaling processes [14; 15; 26] . Our observation that a PPARγ agonist acts at the AT1 A R to rapidly recruit βarr1/2 suggests a lack of role for PPARγ-mediated transcriptional events in this process. With regard to cardiomyocyte function, our data highlights the ability of Trog to induce an acute physiologic response via AT1 A R signaling, increasing cardiomyocyte contractility. These data, coupled with the ARB-sensitive nature of Trog-mediated AT1 A R-β-arrestin signaling, suggest that Trog-mediated effects at the level of AT1 A R are independent of PPARγ activation.
PPARγ agonists, including Trog and ciglitazone, have been previously reported to exert off-target effects, influencing intracellular processes independent of PPARγ activation in different cell lines and tissue [14; 15; 26] . One of these processes involved alterations in intracellular and/or extracellular Ca 2+ -handling, dependent upon the PPARγ agonist, though a role for AT1 A R in this process was not explored [14] . Such effects on Ca 2+ -handling may explain our observation that a portion of the Trog-induced cardiomyocyte contractility was βarr2-independent, as approximately half the contractile response remained in the absence of βarr2 (Fig. 4C) . In our study, we show Trog-mediated AT1 A R effects are independent of G q protein activation but dependent on β-arrestin recruitment. The ability of a 7TMR to utilize β-arrestin to exert downstream signaling is now being recognized as a mechanism to stimulate physiologic effects and accumulating data suggests that β-arrestin-mediated signaling opposes detrimental G protein-mediated activity to confer beneficial cellular effects [3; 6; 27] .
The ability of ligands to stabilize receptors in certain conformations that activate particular signaling pathways but not others has been increasingly explored [28; 29] . [Sar 1 , Ile 4 ,
Ile 8 ]-Ang (SII) was shown to act at the AT1 A R to preferentially enhance β-arrestin-mediated signaling with no effect on G q protein activity and has been suggested to be more cardioprotective than conventional ARBs that prevent both G protein-and β-arrestin-dependent Representative images shown, n = 3 of each condition, scale bar = 10µm. 
